Kanagawa, Japan

Norio Oyabu

This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Norio Oyabu. Retrieved from https://idiyas.com/inventor/norio-oyabu-cfq67tpj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0


Average Co-Inventor Count = 12.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Norio Oyabu: Innovator in AMPA Receptor Function Enhancement

Introduction

Norio Oyabu is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that enhance AMPA receptor function. His work is expected to have a profound impact on the treatment of various neurological disorders.

Latest Patents

Norio Oyabu holds a patent for "Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function." This invention aims to provide a heterocyclic compound that exhibits an AMPA receptor potentiator effect. The compound is anticipated to be useful as an agent for the prophylaxis or treatment of conditions such as depression, Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The patent details a compound represented by a specific formula, including its salts.

Career Highlights

Norio Oyabu is associated with Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company. His work at Takeda has allowed him to focus on innovative solutions for complex health issues. His dedication to research and development has positioned him as a key figure in his field.

Collaborations

Norio Oyabu has collaborated with esteemed colleagues, including Shinji Nakamura and Satoshi Mikami. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in pharmacology.

Conclusion

Norio Oyabu's contributions to the enhancement of AMPA receptor function represent a significant advancement in the treatment of neurological disorders. His innovative work continues to inspire future research and development in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…